Tariff-Resistant Abbott Laboratories on Track for New Highs
Abbott Laboratories (NYSE:) is not immune to the impact of tariffs on its medical device business. However, the company’s diversified business is tariff-resistant, and moves are being made to strengthen it further. Those include a $500 million investment in two domestic manufacturing facilities expected to go live by year’s end. The facilities are located in ...











